Craig E Higgins
Overview
Explore the profile of Craig E Higgins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Czekay R, Higgins C, Aydin H, Samarakoon R, Subasi N, Higgins S, et al.
Cells
. 2024 May;
13(10.
PMID: 38786020
A heterogenous population of inflammatory elements, other immune and nonimmune cells and cancer-associated fibroblasts (CAFs) are evident in solid malignancies where they coexist with the growing tumor mass. In highly...
2.
Higgins C, Tang J, Higgins S, Gifford C, Mian B, Jones D, et al.
Front Cell Dev Biol
. 2021 Jul;
9:678524.
PMID: 34277620
Tubulointerstitial fibrosis is a common and diagnostic hallmark of a spectrum of chronic renal disorders. While the etiology varies as to the causative nature of the underlying pathology, persistent TGF-β1...
3.
Samarakoon R, Higgins S, Higgins C, Higgins P
Biomolecules
. 2019 Aug;
9(8).
PMID: 31382626
Stress-induced premature cellular senescence is a significant factor in the onset of age-dependent disease in the cardiovascular system. Plasminogen activator inhibitor-1 (PAI-1), a major TGF-β1/p53 target gene and negative regulator...
4.
Higgins C, Tang J, Mian B, Higgins S, Gifford C, Conti D, et al.
FASEB J
. 2019 Jul;
33(10):10596-10606.
PMID: 31284746
Chronic kidney disease affects >15% of the U.S. population and >850 million individuals worldwide. Fibrosis is the common outcome of many chronic renal disorders and, although the etiology varies (,...
5.
Higgins S, Tang Y, Higgins C, Mian B, Zhang W, Czekay R, et al.
Cell Signal
. 2017 Dec;
43:1-10.
PMID: 29191563
Fibrotic disorders of the renal, pulmonary, cardiac, and hepatic systems are associated with significant morbidity and mortality. Effective therapies to prevent or curtail the advancement to organ failure, however, remain...
6.
Simone T, Higgins S, Higgins C, Lennartz M, Higgins P
J Mol Genet Med
. 2015 Jun;
8(3).
PMID: 26110015
No abstract available.
7.
Simone T, Higgins S, Archambeault J, Higgins C, Ginnan R, Singer H, et al.
Cell Signal
. 2015 Jan;
27(5):923-33.
PMID: 25617690
Plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of urokinase-and tissue-type plasminogen activators (uPA and tPA), is an injury-response gene implicated in the development of tissue fibrosis and cardiovascular disease. PAI-1...
8.
Qi L, Higgins C, Higgins S, Law B, Simone T, Higgins P
J Cell Biochem
. 2014 Jun;
115(10):1840-7.
PMID: 24905330
Plasminogen activator inhibitor type-1 (PAI-1), a major regulator of the plasmin-dependent pericellular proteolytic cascade, is prominently expressed during the tissue response to injury although the factors that impact PAI-1 induction...
9.
Simone T, Higgins C, Czekay R, Law B, Higgins S, Archambeault J, et al.
Adv Wound Care (New Rochelle)
. 2014 Mar;
3(3):281-290.
PMID: 24669362
A highly interactive serine protease/plasmin/matrix metalloproteinase axis regulates stromal remodeling in the wound microenvironment. Current findings highlight the importance of stringent controls on protease expression and their topographic activities in...
10.
Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer's Disease
Kutz S, Higgins C, Higgins P
Mol Med Ther
. 2013 Jul;
1(2):106.
PMID: 23847772
Accumulation of neurotoxic amyloid peptides (Aβ) in the brain, generated by β-site proteolytic processing of the amyloid precursor protein (APP), is the hallmark pathophysiologic feature of Alzheimer's disease. The plasmin-activating...